- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
ADMA Biologics Inc(ADMA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ADMA
11/20/2026: ADMA (4-star) is a STRONG-BUY. BUY for 38 days. Simulated Profits (31.31%). Updated daily EoD!
ADMA Biologics is a commercial biopharmaceutical company specializing in plasma-derived therapeutics for immunodeficient patients. The company's main strengths reside in its proprietary manufacturing facility and strong sales execution for its flagship product, ASCENIV. Its primary growth story centers on expanding production yields and increasing physician adoption to achieve ambitious multi-year revenue targets. Key risks include intense competition from global plasma giants and potential manufacturing concentration vulnerabilities. The stock suits growth-oriented investors willing to monitor operational execution and regulatory consistency.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company exhibits robust multi-year revenue expansion and high forward growth targets. |
| Momentum investor | Strong fit while signal remains positive | Positive earnings beats and upward revisions can trigger strong momentum trends when technical sentiment aligns. |
| Value investor | Mixed fit | While profitability has turned robust, valuation multiples reflect expectations for continued rapid expansion. |
| Dividend investor | Weak fit | ADMA does not pay dividends, retaining earnings to fuel corporate expansion. |
| Low-risk investor | Weak fit | Biopharmaceutical execution risks and market volatility make it less suitable for conservative capital. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium / high | Biotech equities frequently experience sharper sentiment-driven swings than broader market indices. |
| Valuation risk | Medium | Sustained high multiples leave little room for operational missteps or guidance misses. |
| Competition risk (plasma fractionation dominance) | High | The market is heavily dominated by entrenched global giants with vast capital resources. |
| Business quality | Medium / high | Proprietary manufacturing assets and rising margins indicate solid foundational quality. |
| Dividend income | Low / none | No payouts are offered as cash is prioritized for internal reinvestment. |
| Execution risk | Medium / high | Meeting ambitious long-term financial targets requires flawless operational delivery. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.92B USD | Price to earnings Ratio 17.1 | 1Y Target Price 18 |
Price to earnings Ratio 17.1 | 1Y Target Price 18 | ||
Volume (30-day avg) 3.7M shares | Beta 0.66 | 52 Weeks Range 7.21 - 20.46 | Updated Date 11/20/2026 |
52 Weeks Range 7.21 - 20.46 | Updated Date 11/20/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.77 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.2%
- Active BUY / eligible
- 19 / 44
- 30-Day BUY Count Change
- +12
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Downtrend
The stock has experienced a sustained decline in price over recent periods.

Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 197.49% | Avg. Invested days 45 | Today’s Advisory Strong Buy |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| ADMA BioManufacturing | Revenues derived from the sale of specialty plasma-derived biologics including ASCENIV, BIVIGAM, and NABI-HB. | This is the core profit engine where the company turns raw plasma into high-value immune therapeutics. |
| Plasma Collection Centers | Revenues from plasma collection centers and intermediate fraction sales. | Supports raw material supply security and supplemental operational revenue. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-11-04 | When After Market | Estimate 0.19 | Actual 0.22 |
Profitability
Profit Margin 35.14% | Operating Margin (TTM) 44.93% |
Management Effectiveness
Return on Assets (TTM) 22.41% | Return on Equity (TTM) 41.95% |
Valuation
Trailing PE 17.1 | Forward PE 13.61 | Enterprise Value 3.04B | Price to Sales(TTM) 5.63 |
Enterprise Value 3.04B | Price to Sales(TTM) 5.63 | ||
Enterprise Value to Revenue 5.85 | Enterprise Value to EBITDA 12.03 | Shares Outstanding 221.85M | Shares Floating 205.22M |
Shares Outstanding 221.85M | Shares Floating 205.22M | ||
Percent Insiders 1.97 | Percent Institutions 92.94 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

